I am a
Home I AM A Search Login

Papers of the Week

2022 Oct 21

Pediatr Dermatol

Atopic dermatitis-like graft-versus-host disease treated with dupilumab.


Larijani M, Zarowin D, Wohlschlaeger A, Perman MJ, Treat JR
Pediatr Dermatol. 2022 Oct 21.
PMID: 36268606.


The mainstay of treatment for atopic dermatitis (AD)-like graft-versus-host disease (GVHD) in both pediatric and adult patients includes oral corticosteroids with or without other systemic immunosuppressive therapies. To our knowledge, we report the first case series of dupilumab in the treatment of AD-like GVHD in a pediatric cohort of four patients, where we observed clinical improvement of GVHD as well as a reduction in itch in 3/4 (75%) patients. Our findings suggest that dupilumab is not only effective in treating AD-like GVHD, but also reduces systemic immunosuppression in the pediatric transplant population. The ability to reduce the length and amount of immunosuppression as well as improve quality of life suggest that dupilumab may serve as a safe and effective therapeutic option in our transplant population with GVHD.